
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        G:\APPS\EdgarEasePlus\Hemagen\form8k121704.eep                   -->
     <!-- Control Number: HE5180                                                           -->
     <!-- Rev Number:                                                                      -->
     <!-- Client Name:    Hemagen Diagnostics Inc.                                         -->
     <!-- Project Name:   Form 8-K - 12/17/2004                                            -->
     <!-- Firm Name:      KMK                                                              -->
     <TITLE>Exhibit 99</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left-TNR" FSL="Workstation" -->
<P ALIGN="Right"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exhibit
99</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH=100%>
<TR VALIGN="TOP">
     <TD WIDTH="50%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>NEWS BULLETIN</B>
</FONT></TD>
     <TD ALIGN="RIGHT" WIDTH="50%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>HEMAGEN(R)DIAGNOSTICS, INC.</B><BR>
9033 Red Branch Road, Columbia, MD  21045
</FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>AT THE COMPANY: </U><BR>
William P. Hales, President &amp; CEO <BR>(443) 367-5500 Tel.<BR>(443) 367-5527 Fax </FONT></P>

<hr>




<TABLE WIDTH="100%" BORDER="0" CELLPADDING="0" CELLSPACING="0">
<TR VALIGN="BOTTOM">
     <TH><FONT SIZE="2"></FONT></TH>
     <TH><FONT SIZE="2"></FONT></TH></TR>
<TR VALIGN="TOP">
     <TD WIDTH="50%"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">FOR IMMEDIATE RELEASE <BR>
December 17, 2004
</FONT></TD>
     <TD WIDTH="50%" ALIGN="Right"><FONT FACE="Times New Roman, Times, Serif" SIZE="2">OTC: HMGN.OB
</FONT></TD></TR>
</TABLE>


<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>HEMAGEN EXTENDS
EXCHANGE OFFER FOR 8% SENIOR SUBORDINATED<BR>SECURED CONVERTIBLE
NOTES DUE APRIL 2005</U>  </FONT></H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>COLUMBIA, MD &#150; Hemagen
Diagnostics, Inc., (NASDAQ: HMGN.OB) announced today that it has extended its offer to
exchange $6,090,000 principal amount of its 8% Senior Subordinated Secured Convertible
Notes due 2005 (the &#147;Notes&#148;) for common stock and Modified Notes. The exchange
offer, as previously extended, was scheduled to expire at 12:00 midnight, Eastern Time, on
December 17, 2004. The new expiration date for the exchange offer is 12:00 midnight,
Eastern Time, on December 21, 2004, unless further extended or earlier terminated. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>To date, $5,765,000 or 94.7% of the
principal amount of the Notes have been deposited for exchange. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release is neither an
offer to purchase nor a solicitation of an offer to sell securities of Hemagen
Diagnostics, Inc. The exchange offer will be made only through and upon the terms and
conditions described in Hemagen Diagnostics, Inc&#146;s Offering Memorandum dated
September&nbsp;2, 2004, as supplemented, and related letter of transmittal. Hemagen has
filed a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission.
The Tender Offer Statement (including an offering circular, a related letter of
transmittal and other offering documents) contains important information that should be
read carefully before any decision is made with respect to the offer. The Offering
Memorandum, as supplemented, the related letter of transmittal and certain other documents
are being sent to all holders of Hemagen, existing Notes, at no expense to them. The
Tender Offer Statement (including the offering circular, the related letter of transmittal
and all other documents filed with the Securities and Exchange Commission) are available
at no charge at the Securities and Exchange Commission website at <U>http://sec.gov</U> or
from Hemagen at <U>dricci@hemagen.com</U>. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Investors may also contact
Mr.&nbsp;Hales, at Hemagen Diagnostics, Inc., to obtain information about the exchange
offer, including copies of the offering circular and related documents. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Hemagen Diagnostics, Inc., is a
biotechnology company that develops, manufactures, and markets more than 150 FDA-cleared
proprietary medical diagnostic test kits used to aid in the diagnosis of certain
autoimmune and infectious diseases. Hemagen also manufactures and markets a complete line
of Clinical Chemistry Reagents through its wholly owned subsidiary RAICHEM. In addition,
Hemagen manufactures and sells the Analyst&reg; an FDA-cleared Clinical Chemistry Analyzer
used to measure important constituents in human and animal blood, and the Endochek, a
clinical chemistry analyzer used to measure important constituents in animal blood. In the
United States, the Company sells its products directly to physicians, veterinarians,
clinical laboratories and blood banks and on a private-label basis through multinational
distributors of medical supplies. Internationally, the Company sells its products
primarily through distributors. The Company sells the Analyst&reg; and the Endochek both
directly and through distributors servicing physicians&#146; office laboratories and
veterinarians&#146; offices. Hemagen&#146;s products are used in many of the largest
Laboratories, Hospitals, and Blood Banks around the world. Hemagen sells its products to
over 1,000 customers worldwide. The company focuses on markets that offer significant
growth opportunities. The Company was incorporated in 1985 and became a public company in
1993. </FONT></P>

<!-- MARKER FORMAT-SHEET="Page Rule Single" FSL="Default" -->
     <HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Except for any historical information
contained herein, the matters discussed in this press release contain forward-looking
statements that involve risks and uncertainties, including those described in the
Company&#146;s Securities and Exchange Commission Reports and Filings. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Certain Statements contained in this
News Bulletin that are not historical facts constitute forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to
be covered by the safe harbors created by that Act. Reliance should not be placed on
forward looking statements because they involve unknown risks, uncertainties and other
factors which may cause actual results, performance or achievements to differ materially
from those expressed or implied. Forward looking statements may be identified by words
such as estimates, anticipates, projects, plans, expects, intends, believes, should and
similar expressions and by the context in which they are used. Such statements are based
upon current expectations of the Company and speak only as of the date made. The Company
undertakes no obligation to update any forward-looking statements to reflect events or
circumstances after the date on which they are made. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Statements concerning the
establishments of reserves and adjustments for dated and obsolete products, expected
financial performance, on-going business strategies and possible future action, which
Hemagen intends to pursue to achieve strategic objectives, constitute forward-looking
information. The sufficiency of such reserves and adjustments, expected performance,
implementation of on-going business strategies and possible future action, the achievement
of financial performance are each subject to numerous conditions, uncertainties and risk
factors. Factors which could cause actual performance to differ materially from these
forward looking statements, include without limitation, management&#146;s analysis of
Hemagen&#146;s assets, liabilities and operations, the failure to sell date sensitive
inventory prior to its expiration, the inability of particular products to support
goodwill allocated to them, competition, new product development by competitors which
could render particular products obsolete, the inability to develop or acquire and
successfully introduce new products or improvements of existing product costs and
difficulties in complying with laws and regulations administered by the U. S. Food and
Drug Administration and the ability to assimilate successfully product acquisitions. </FONT></P>
</BODY>
</HTML>

